Tenax Therapeutics Files Proxy Statement for Annual Meeting
Ticker: TENX · Form: DEF 14A · Filed: Sep 27, 2024 · CIK: 34956
| Field | Detail |
|---|---|
| Company | Tenax Therapeutics, INC. (TENX) |
| Form Type | DEF 14A |
| Filed Date | Sep 27, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 20 min |
| Key Dollar Amounts | $3.7389, $100 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
TL;DR
Tenax Proxy filed - vote on directors & auditors soon.
AI Summary
Tenax Therapeutics, Inc. filed its definitive proxy statement on September 27, 2024, for its annual meeting of stockholders. The filing outlines the proposals to be voted on, including the election of directors and the ratification of the appointment of its independent registered public accounting firm. The company is seeking shareholder approval for these matters to ensure continued corporate governance and financial oversight.
Why It Matters
This filing is crucial for shareholders as it details the agenda for the annual meeting, allowing them to make informed decisions on company leadership and financial auditing.
Risk Assessment
Risk Level: low — This is a routine annual filing detailing corporate governance matters and does not present new financial risks.
Key Players & Entities
- TENAX THERAPEUTICS, INC. (company) — Registrant
- 0001654954-24-012375 (dollar_amount) — Accession Number
- 20240927 (dollar_amount) — Filing Date
- 20241025 (dollar_amount) — Fiscal Year End
FAQ
What is the purpose of this DEF 14A filing?
The purpose of this DEF 14A filing is to provide shareholders with the definitive proxy statement for Tenax Therapeutics, Inc.'s annual meeting of stockholders, outlining proposals for voting.
When was this filing made?
This filing was made on September 27, 2024.
What are the main items shareholders will vote on?
Shareholders will vote on proposals including the election of directors and the ratification of the appointment of the independent registered public accounting firm.
What is the company's address?
The company's business and mailing address is 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC 27517.
Has the company changed its name previously?
Yes, Tenax Therapeutics, Inc. was formerly known as Oxygen Biotherapeutics, Inc. (name change 20080703), Synthetic Blood International Inc (name change 19920703), and Sinequanon Corp (name change 19901219).
Filing Stats: 4,915 words · 20 min read · ~16 pages · Grade level 12.6 · Accepted 2024-09-27 08:14:24
Key Financial Figures
- $3.7389 — apital Market on September 10, 2024 was $3.7389. Required Vote and Related Voting Arra
- $100 million — nd sold to such Investors approximately $100 million (the "Financing Amount") of the Company
Filing Documents
- tenx_def14a.htm (DEF 14A) — 440KB
- tenx_def14aimg3.jpg (GRAPHIC) — 7KB
- tenx_def14aimg4.jpg (GRAPHIC) — 24KB
- tenx_def14aimg5.jpg (GRAPHIC) — 115KB
- tenx_def14aimg6.jpg (GRAPHIC) — 121KB
- 0001654954-24-012375.txt ( ) — 809KB
Executive Compensation
Executive Compensation 16 Director Compensation 25
Security Ownership of Certain Beneficial Owners and Management
Security Ownership of Certain Beneficial Owners and Management 26 Stockholder Proposals 30 Householding Materials 30 Annual Report on Form 10-K 30 Requests for Directions to the Special Meeting 31 Other Matters 31 Annex A: Amendment No. 2 to the Tenax Therapeutics, Inc. 2022 Stock Incentive Plan A-1 ii Table of Contents TENAX THERAPEUTICS, INC. PROXY STATEMENT SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON OCTOBER 25, 2024 Information Concerning Solicitation and Voting The Notice of Special Meeting of Stockholders, Proxy Statement and Form of Proxy are available at https://investors.tenaxthera.com/sec-filings and www.proxyvote.com This Proxy Statement is furnished to the holders of our common stock in connection with the solicitation of proxies on behalf of our Board of Directors for use at the Special Meeting to be held on October 25, 2024, at 9:00 a.m., Eastern Time at 101 Glen Lennox Drive, Suite 300, Chapel Hill, North Carolina, or for use at any adjournment or postponement thereof, for the purposes set forth herein and in the accompanying Notice of Special Meeting of Stockholders. Only stockholders of record at the close of business on September 10, 2024 (the "Record Date") are entitled to notice of and to vote at the Special Meeting. We mailed our proxy materials on or about September 27, 2024 to our stockholders of record and beneficial owners as of the close of business on the Record Date. Each holder of our common stock is entitled to one vote for each share held as of the Record Date with respect to all matters that may be considered at the Special Meeting. Stockholder votes will be tabulated by persons appointed by our Board of Directors to act as inspectors of election for the Special Meeting. We bear the expense of soliciting proxies. Our directors, officers, and employees may also solicit proxies personally or by telephone, facsimile, or other means of communication. We do not intend to pay additional compensatio